Incidence and risk factors of trastuzumab-induced cardiac dysfunction in a predominantly Hispanic South Texas population: a descriptive study

Abstract Background Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2), is often the first line treatment for HER2 positive breast cancer. Although trastuzumab is effective, it has cardiotoxic effects and therefore requires cardiotoxicity monitoring via serial...

Full description

Bibliographic Details

Published in:	Cardio-Oncology
Main Authors:	Aditi Sharma, Maria E. Fierro, Samuel Governor, Aishwarya Kothare, Stella Pak, Karen Liu, Zuha Alam, Prince Otchere
Format:	Article
Language:	English
Published:	BMC 2025-02-01
Subjects:	Trastuzumab Cardiotoxicity Cardio-oncology Health disparities Breast cancer
Online Access:	https://doi.org/10.1186/s40959-025-00319-4